Drug intelligence / Profile preview

HTO-066

Development stage: Preclinical
Lead developer: Carna Biosciences
Modality: Small Molecules
Administration: Subcutaneous

Overview

HTO-066 is an investigational small-molecule tyrosine kinase 2 (TYK2) agonist initially developed by Carna Biosciences for potential immunology-related indications, and is currently reported to be in preclinical development. As a TYK2 agonist, it is designed to modulate Janus kinase–signal transducer and activator of transcription (JAK–STAT) signaling pathways in immune cells, although detailed target profile, indication focus, and pharmacologic data have not yet been publicly disclosed.

Targets

TYK2 (Tyrosine kinase 2)

Beyond the preview

Go deeper on HTO-066.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HTO-066.

Explore the full profile